Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117096) titled 'Individualized dose of remazolam besylate for painless bronchoscopy in elderly patients and its effect on emergence delirium' on Jan. 20.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Guizhou Aerospace Hospital
Condition:
None
Intervention:
Remimazolam besylate group:Remimazolam besylate (ED95 from phase I) was used for induction and maintenance.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-01
Target Sample Size: Remimazolam besylate group:60; AI Propofol group(YNMT)· :60;
Countries of Recruitment:
China
To know more, visit ...